Central Trust Company’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Central Trust Company’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-200	Closed	–	–	1433
2017 Q2	$0	Hold	200	–	–	﹤0.01%	1376
2017 Q1	$0	Hold	200	–	–	﹤0.01%	1260
2016 Q4	$0	Hold	200	–	–	﹤0.01%	1244
2016 Q3	$0	Hold	200	–	–	﹤0.01%	1238
2016 Q2	$0	Hold	200	–	–	﹤0.01%	1209
2016 Q1	$1K	Hold	200	–	–	﹤0.01%	1105
2015 Q4	$3K	Hold	200	–	–	﹤0.01%	1117
2015 Q3	$4K	Hold	200	–	–	﹤0.01%	1117
2015 Q2	$10K	Hold	200	–	–	﹤0.01%	1016
2015 Q1	$16K	Hold	200	–	–	﹤0.01%	903
2014 Q4	$12K	Hold	200	–	–	﹤0.01%	953
2014 Q3	$9K	Hold	200	–	–	﹤0.01%	1010
2014 Q2	$12K	Buy	+200	New	+$11.6K	﹤0.01%	944

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Central Trust Company's OREX Position: Q3 2017 in Review

Central Trust Company sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2017, closing a stake of 200 shares.

Central Trust Company first reported a position in OREX in Q2 2014 and held it in 13 quarters. The position peaked at $16K in Q1 2015. 42 funds tracked by Wall St. Rank hold OREX as of Q3 2017.

Central Trust Company reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
Central Trust Company sold 200 Orexigen Therapeutics, Inc. shares in Q3 2017.
Central Trust Company first reported a position in Orexigen Therapeutics, Inc. in Q2 2014 and held it in 13 quarters.
Central Trust Company's Orexigen Therapeutics, Inc. position peaked at $16K in Q1 2015.
42 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2017.

Based on Central Trust Company's 13F filing for Q3 2017, filed 17 Oct 2017.